🔎 Trials Near Me

Home › Squamous Cell Carcinoma ng Ulo at Leeg › Oregon

Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa Oregon

19 pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa mga site sa Oregon.

Mga Lungsod sa Oregon

Opisyal na teksto ng pag-aaral (English)

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

  • ALX Center 6, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07085091

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06589804

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

  • Site 02, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07814248

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT05877599

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  • Oregon Health And Science University, Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07276399

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

  • Oregon Health and Science University, Portland
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06980038

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  • Saint Charles Health System, Bend
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05136196

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  • Oregon Health And Science University, Portland
Nagre-recruitPhase 3
Edad 60 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04892173

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Nagre-recruitPhase 2
Edad 18 hanggang 79 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT04671667

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • at 8 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT02734537

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT04895709

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

  • Clackamas Radiation Oncology Center, Clackamas
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT04333537

A Study of MGC026 in Participants With Advanced Solid Tumors

  • Providence Cancer Institute, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06242470

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #51, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT05176483

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  • Site #0113, Portland
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 17, 2026 · NCT06788990

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • Providence Cancer Institute Franz Clinic, Portland
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT05768139

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Providence Cancer Institute Franz Clinic, Portland
  • Providence Oncology and Hematology Care Clinic - Westside, Portland
  • Providence St. Vincent Medical Center- Investigational Drug Services, Portland
  • at 1 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04389632

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

  • OHSU Knight Cancer Institute, Portland
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 12, 2026 · NCT07405086

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA15-0, Portland
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 22, 2026 · NCT06953089

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.